Xuesong Han, PhD
Scientific Director
Health Services Research
What Keeps Me Going
I never lose sight of the fact that most people are affected by cancer in some way—personally, as a caregiver to a family member or friend, or from losing someone they love. As a scientist, I am dedicated to helping them by designing and conducting research that can be used to support health policies that can improve cancer survival and better ensure that patients and their families can maximize quality of life.”
At ACS since 2012
Xuesong Han, PhD, is the Scientific Director of Health Services Research in the Surveillance & Health Equity Science department of the American Cancer Society (ACS). She leads cancer disparities research related to health insurance coverage and aspects of the Affordable Care Act.
Research focus and accomplishments
Han’s research examines disparities in cancer prevention, diagnosis, treatment, and survival associated with health insurance and socioeconomic status. She also studies the changes that can result from implementing new healthcare policies.
She also collaborates on cancer survivorship research studies, addressing economic burden, financial hardship, employment changes, psychosocial distress, and health-related quality of life.
Han holds adjunct faculty appointments at the Rollins School of Public Health and the Winship Cancer Institute, Emory University.
Publications
For a full list of Dr. Han’s publications, see her Google Scholar page.
Contact
Work before ACS
- Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Research Assistant Professor and Marilyn Gentry Fellow
Professional organizations
- AcademyHealth, Member
- American Association for Cancer Research, Member
- American Society of Clinical Oncology, Member
- China Health Policy and Management Society, Founding member
Education
- PhD: Epidemiology & Public Health, Yale University, 2010
- MEng: Biochemical Engineering, Tsinghua University, 2004
- BEng: Chemical Engineering, Tsinghua University, 2001
Help us end cancer as we know it, for everyone.
